Paul Shin Email

SVP, R&D Operations . 89bio

Current Roles

Employees:
104
Revenue:
$16.1M
About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making
89bio Address
142 Sansome Street
null, null
89bio Email

Past Companies

89bioSenior Vice President, R&D Operations
Intercept Pharmaceuticals, Inc.Vice President, Global Head, Clinical Operations
Nestlé Health ScienceGlobal Head of Research & Development Operations

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.